.25 mg of semaglutide Medscape | The FDA has approved once-daily oral 25 (Wegovy Pill, Novo Nordisk) as the first GLP-1 agonist pill for weight management. ⁠ Semaglo | Semaglutide 0.25mg Subcutaneous

This is because in addition to reducing and controlling appetite, it also stimulates another hormone, GIP, which is thought to improve how the body breaks down sugar and fat

Retatrutide is a triple agonist (GIP/GLP-1/glucagon) currently in clinical trials that has shown weight loss exceeding 24% of body weight

This occurs because beta-blockers remove a small 2 -adrenoceptor vasodilator influence (e.g., originating from circulating epinephrine) that is normally opposing the more dominant alpha-adrenoceptor mediated vasoconstrictor influence originating from sympathetic tone

Lets get you back into the clothes you love!

These inequities are compounded by limited insurance and public payer coverage along with provider bias and geographic inequities that restrict access in underserved communities